Gene targeting techniques for Huntington’s disease

Anzalone, 2019, Search-and-replace genome editing without double-strand breaks or donor DNA, Nature, 576, 149, 10.1038/s41586-019-1711-4 Anzalone, 2020, Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors, Nat. Biotechnol., 38, 824, 10.1038/s41587-020-0561-9 Aziz, 2008, Weight loss in Huntington disease increases with higher CAG repeat number, Neurology, 71, 1506, 10.1212/01.wnl.0000334276.09729.0e Bae, 2005, p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease, Neuron, 47, 29, 10.1016/j.neuron.2005.06.005 Bañez-Coronel, 2015, RAN translation in huntington disease, Neuron, 88, 667, 10.1016/j.neuron.2015.10.038 Barnat, 2020, Huntington’s disease alters human neurodevelopment, Science, 369, 787, 10.1126/science.aax3338 Bates, 2015, Huntington disease, Nat. Rev. Dis. Primer, 1, 1, 10.1038/nrdp.2015.5 Benn, 2020, Drugging DNA damage repair pathways for trinucleotide repeat expansion diseases, J. Huntingt. Dis., 1 Bennett, 2010, RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform, Annu. Rev. Pharmacol. Toxicol., 50, 259, 10.1146/annurev.pharmtox.010909.105654 Boudreau, 2009, Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington’s Disease Mice, Mol. Ther., 17, 1053, 10.1038/mt.2009.17 Boxer, 2019, Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial, Lancet Neurol., 18, 549, 10.1016/S1474-4422(19)30139-5 Chao, 2017, Haplotype-based stratification of Huntington’s disease, Eur. J. Hum. Genet., 25, 1202, 10.1038/ejhg.2017.125 Choi, 2018, Comparison of phasing strategies for whole human genomes, PLoS Genet., 14, 10.1371/journal.pgen.1007308 Datson, 2017, The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain, PLoS One, 12, 10.1371/journal.pone.0171127 de Almeida, 2002, Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length, J. Neurosci., 22, 3473, 10.1523/JNEUROSCI.22-09-03473.2002 Di Fusco, 2019, Antisense oligonucleotide: basic concepts and therapeutic application in inflammatory bowel disease, Front. Pharmacol., 10, 305, 10.3389/fphar.2019.00305 Dragatsis, 2000, Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice, Nat. Genet., 26, 300, 10.1038/81593 Drouet, 2009, Sustained effects of nonallele-specific Huntingtin silencing, Ann. Neurol., 65, 276, 10.1002/ana.21569 Ehrnhoefer, 2011, Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease, Neurosci. Rev. J. Bringing Neurobiol. Neurol. Psychiatry, 17, 475 Elias, 2014, Huntingtin regulates mammary stem cell division and differentiation, Stem Cell Rep., 2, 491, 10.1016/j.stemcr.2014.02.011 Elsner, 2012, Single-stranded siRNAs for in vivo gene silencing, Nat. Biotechnol., 30, 1063, 10.1038/nbt.2413 Fan, 2014, Polyglutamine (PolyQ) diseases: genetics to treatments, Cell Transplant., 23, 441, 10.3727/096368914X678454 Fernández-Nogales, 2020, Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington’s Disease, Front. Cell. Neurosci., 13, 574, 10.3389/fncel.2019.00574 Foster, 2013, Gut–brain axis: how the microbiome influences anxiety and depression, Trends Neurosci., 36, 305, 10.1016/j.tins.2013.01.005 Golubeva, 2017, Microbiota-related changes in bile acid & tryptophan metabolism are associated with gastrointestinal dysfunction in a mouse model of autism, EBioMedicine, 24, 166, 10.1016/j.ebiom.2017.09.020 Greenblum, 2012, Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease, Proc. Natl. Acad. Sci. U.S.A., 109, 594, 10.1073/pnas.1116053109 Grima, 2017, Mutant huntingtin disrupts the nuclear pore complex, Neuron, 94, 93, 10.1016/j.neuron.2017.03.023 Grondin, 2012, Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum, Brain, 135, 1197, 10.1093/brain/awr333 Gubert, 2020, Why Woody got the blues: the neurobiology of depression in Huntington’s disease, Neurobiol. Dis., 142, 10.1016/j.nbd.2020.104958 Harding, 2018, Proteostasis in Huntington’s disease: disease mechanisms and therapeutic opportunities, Acta Pharmacol. Sin., 39, 754, 10.1038/aps.2018.11 Haremaki, 2015, Huntingtin is required for ciliogenesis and neurogenesis during early Xenopus development, Dev. Biol., 408, 305, 10.1016/j.ydbio.2015.07.013 Humbert, 2002, The IGF-1/Akt Pathway Is Neuroprotective in Huntington’s Disease and Involves Huntingtin Phosphorylation by Akt, Dev. Cell, 2, 831, 10.1016/S1534-5807(02)00188-0 Hutvagner, 2008, Argonaute proteins: key players in RNA silencing, Nat. Rev. Mol. Cell Biol., 9, 22, 10.1038/nrm2321 Jones, 2011, Pathogenic mechanisms in Huntington’s disease, 373 Keryer, 2011, Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease, J. Clin. Invest., 121, 4372, 10.1172/JCI57552 Koblan, 2021, In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice, Nature, 589, 608, 10.1038/s41586-020-03086-7 Kong, 2020, Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington’s disease, Neurobiol. Dis., Microbiome in neurological and psychiatric disease, 135 Kordasiewicz, 2012, Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis, Neuron, 74, 1031, 10.1016/j.neuron.2012.05.009 Landles, 2004, Huntingtin and the molecular pathogenesis of Huntington’s disease, EMBO Rep., 5, 958, 10.1038/sj.embor.7400250 Larrouy, 1992, RNase H-mediated inhibition of translation by antisense oligodeoxyribo-nucleotides: use of backbone modification to improve specificity, Gene, 121, 189, 10.1016/0378-1119(92)90121-5 Leavitt, 2020, Huntingtin-lowering therapies for huntington disease: a review of the evidence of potential benefits and risks, JAMA Neurol., 77, 764, 10.1001/jamaneurol.2020.0299 Lebouc, 2020, Striatal circuit development and its alterations in Huntington’s disease, Neurobiol. Dis., 145, 10.1016/j.nbd.2020.105076 Lee, 2012, CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion, Neurology, 78, 690, 10.1212/WNL.0b013e318249f683 Li, 2009, Mutant huntingtin impairs vesicle formation from recycling endosomes by interfering with Rab11 activity, Mol. Cell. Biol., 29, 6106, 10.1128/MCB.00420-09 Li, 2019, Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds, Nature, 575, 203, 10.1038/s41586-019-1722-1 Lipe, 2009, Late onset huntington disease: clinical and genetic characteristics of 34 cases, J. Neurol. Sci., 276, 159, 10.1016/j.jns.2008.09.029 Lu, 2012, “Huntingtin Holiday”: Progress toward an Antisense Therapy for Huntington’s Disease, Neuron, 74, 964, 10.1016/j.neuron.2012.06.001 Luo, 2005, Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases implications for mutant huntingtin toxicity, J. Cell Biol., 169, 647, 10.1083/jcb.200412071 Machiela, 2020, Biological Aging and the Cellular Pathogenesis of Huntington’s Disease, J. Huntingt. Dis., 9, 115, 10.3233/JHD-200395 Mangiarini, 1996, Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice, Cell, 87, 493, 10.1016/S0092-8674(00)81369-0 Martin, 2018, A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease, Sci. Rep., 8, 8096, 10.1038/s41598-018-25903-w McBride, 2011, Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington’s Disease, Mol. Ther., 19, 2152, 10.1038/mt.2011.219 Monteys, 2017, CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo, Mol. Ther., 25, 12, 10.1016/j.ymthe.2016.11.010 Nasir, 1995, Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes, Cell, 81, 811, 10.1016/0092-8674(95)90542-1 NCBI, 2021 Orsini, 2018, Cognitive impairment in neuromuscular diseases: a systematic review, Neurol. Int., 10, 10.4081/ni.2018.7473 Paulsen, 2001, Neuropsychiatric aspects of Huntington’s disease, J. Neurol. Neurosurg. Psychiatry, 71, 310, 10.1136/jnnp.71.3.310 Pla, 2013, Huntingtin acts non cell-autonomously on hippocampal neurogenesis and controls anxiety-related behaviors in adult mouse, PLoS One, 8, 10.1371/journal.pone.0073902 Qin, 2012, A metagenome-wide association study of gut microbiota in type 2 diabetes, Nature, 490, 55, 10.1038/nature11450 Qureshi, 2018, A randomized, single ascending dose study of intravenous BIIB092 in healthy participants, Alzheimers Dement. Transl. Res. Clin. Interv., 4, 746, 10.1016/j.trci.2018.10.007 Ran, 2013, Genome engineering using the CRISPR-Cas9 system, Nat. Protoc., 8, 2281, 10.1038/nprot.2013.143 Rodrigues, 2018, Huntington’s disease clinical trials corner: february 2018, J. Huntingt. Dis., 7, 89, 10.3233/JHD-189001 Rué, 2016, Targeting CAG repeat RNAs reduces Huntington’s disease phenotype independently of huntingtin levels, J. Clin. Invest., 126, 4319, 10.1172/JCI83185 Sathasivam, 2013, Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease, Proc. Natl. Acad. Sci. U. S. A., 110, 2366, 10.1073/pnas.1221891110 Saudou, 1998, Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions, Cell, 95, 55, 10.1016/S0092-8674(00)81782-1 Scheperjans, 2015, Gut microbiota are related to Parkinson’s disease and clinical phenotype, Mov. Disord., 30, 350, 10.1002/mds.26069 Schilling, 1999, Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-Terminal fragment of huntingtin, Hum. Mol. Genet., 8, 397, 10.1093/hmg/8.3.397 Schulte, 2011, The biological function of the Huntingtin protein and its relevance to Huntington’s Disease pathology, Curr. Trends Neurol., 5, 65 Scoles, 2019, Antisense oligonucleotides: a primer, Neurol. Genet., 5, e323, 10.1212/NXG.0000000000000323 Shin, 2016, Permanent inactivation of Huntington’s disease mutation by personalized allele-specific CRISPR/Cas9, Hum. Mol. Genet., 25, 4566 Sopko, 2020, Characterization of tau binding by gosuranemab, Neurobiol. Dis., 146, 10.1016/j.nbd.2020.105120 Southwell, 2009, Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington’s disease, J. Neurosci. Off. J. Soc. Neurosci., 29, 13589, 10.1523/JNEUROSCI.4286-09.2009 Stan, 2020, Increased intestinal permeability and gut dysbiosis in the R6/2 mouse model of Huntington’s disease, Sci. Rep., 10, 10.1038/s41598-020-75229-9 Stanek, 2014, Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of huntington’s disease, Hum. Gene Ther., 25, 461, 10.1089/hum.2013.200 Tabrizi, 2019, Targeting Huntingtin Expression in Patients with Huntington’s Disease, N. Engl. J. Med., 380, 2307, 10.1056/NEJMoa1900907 Tabrizi, 2020, Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities, Nat. Rev. Neurol., 16, 529, 10.1038/s41582-020-0389-4 Thompson, 2009, IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome, J. Cell Biol., 187, 1083, 10.1083/jcb.200909067 Thomson, 2018, Transcriptional regulation of the huntingtin gene, J. Huntingt. Dis., 7, 289, 10.3233/JHD-180331 Turnbaugh, 2006, An obesity-associated gut microbiome with increased capacity for energy harvest, Nature, 444, 1027, 10.1038/nature05414 van der Plas, 2020, The Neurodevelopmental Hypothesis of Huntington’s Disease, J. Huntingt. Dis., 9, 217, 10.3233/JHD-200394 Vogt, 2017, Gut microbiome alterations in Alzheimer’s disease, Sci. Rep., 7, 13537, 10.1038/s41598-017-13601-y Walker, 2007, Huntington’s disease, Lancet, 369, 218, 10.1016/S0140-6736(07)60111-1 Wang, 2014, Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington’s disease, Nat. Med., 20, 536, 10.1038/nm.3514 Wang, 2016, Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis, PNAS, 113, 3359, 10.1073/pnas.1524575113 Wasser, 2020, Gut dysbiosis in Huntington’s disease: associations among gut microbiota, cognitive performance and clinical outcomes, Brain Commun, 2, 10.1093/braincomms/fcaa110 Wild, 2017, Therapies targeting DNA and RNA in Huntington’s disease, Lancet Neurol., 16, 837, 10.1016/S1474-4422(17)30280-6 Yang, 2002, Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells, Hum. Mol. Genet., 11, 2905, 10.1093/hmg/11.23.2905 Yu, 2012, Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression, Cell, 150, 895, 10.1016/j.cell.2012.08.002